Condition

Burkitt lymphoma

Clinical trials and treatment information for Burkitt lymphoma

127K
People Affected
80
Active Trials
51K
New Cases/Year
6,526
Deaths/Year

Treatment Rankings

Ranked by evidence volume first. Medicine has spent centuries ranking things by vibes. This is an improvement.

1
Rituximab with GMALL-B-ALL-BFM
90% Effectiveness• 95% Confidence• 25% Safety• 35 trials• 3.5K participants
HIGH EvidenceExcellent ValueDose: Complex multi-drug, multi-phase inpatient regimen, intravenously
Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe

Time to Effect

Within weeks of starting cycles

Duration

4-6 months (multiple blocks)

Response Rate

90%

Remission Rate

85%

Common Side Effects:

Myelosuppression (Neutropenia, Thrombocytopenia, Anemia): 95%
Febrile Neutropenia/Infection: 60%
Mucositis/Stomatitis: 70%
Nausea/Vomiting: 85%
Fatigue: 80%
Alopecia: 90%
Neurotoxicity (Vincristine-induced): 30%
Cardiotoxicity (Doxorubicin-induced): 8%

Annual Cost of Care

Drug Cost

$130,000

Monitoring

$90,000

Side Effects

$55,000

Total Annual

$275,000

Cost-Effectiveness

EXCELLENT

QALYs Gained

6

ICER

$45,833/QALY

Cost per Remission

$323,529.41

Cost per Responder

$305,555.56

Treatment Outcomes
Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+90%
Remission Rate
+85%
Common Side Effects
Myelosuppression (Neutropenia, Thrombocytopenia, Anemia)
+95%
Febrile Neutropenia/Infection
+60%
Mucositis/Stomatitis
+70%

Clinical Trial Phases:

Phase 2Phase 3Phase 4
2
Rituximab with CODOX-M/IVAC
88% Effectiveness• 95% Confidence• 25% Safety• 2 trials• 4K participants
HIGH EvidenceGood ValueDose: Complex multi-drug, dose-intensive regimen, intravenously in inpatient setting
Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe

Time to Effect

Within weeks of starting cycles

Duration

4-5 months (4-6 cycles)

Response Rate

85%

Remission Rate

80%

Common Side Effects:

Myelosuppression (Neutropenia, Thrombocytopenia, Anemia): 95%
Febrile Neutropenia/Infection: 55%
Mucositis/Stomatitis: 65%
Nausea/Vomiting: 80%
Fatigue: 80%
Alopecia: 90%
Neurotoxicity (Vincristine-induced): 35%
Renal Toxicity (Methotrexate, Ifosfamide-induced): 15%

Annual Cost of Care

Drug Cost

$140,000

Monitoring

$75,000

Side Effects

$65,000

Total Annual

$280,000

Cost-Effectiveness

GOOD

QALYs Gained

5

ICER

$60,000/QALY

Cost per Remission

$350,000

Cost per Responder

$329,411.76

Treatment Outcomes
Primary Outcomes
3-year Event-Free Survival Rate65% (with CODOX-M/IVAC alone)
+20% (+13 percentage points)
3-year Overall Survival Rate72% (with CODOX-M/IVAC alone)
+18.1% (+13 percentage points)
Complete Response Rate85% (with CODOX-M/IVAC alone)
+5.9% (+5 percentage points)
Secondary Benefits
3-year Progression-Free Survival Rate68% (with CODOX-M/IVAC alone)
+17.6% (+12 percentage points)
Risk of Relapse (at 3 years)30% (with CODOX-M/IVAC alone)
-33.3% (-10 percentage points)
Common Side Effects
Myelosuppression (Neutropenia, Thrombocytopenia, Anemia)
+95%
Febrile Neutropenia/Infection
+55%
Mucositis/Stomatitis
+65%

Clinical Trial Phases:

Phase 2Phase 3Phase 4
3
Rituximab with Hyper-CVAD/MA
87% Effectiveness• 95% Confidence• 25% Safety• 50 trials• 5K participants
HIGH EvidenceGood ValueDose: Complex multi-drug, dose-intensive regimen, intravenously in inpatient setting
Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe

Time to Effect

Within weeks of starting cycles

Duration

4-6 months (6-8 cycles)

Response Rate

90%

Remission Rate

85%

Common Side Effects:

Myelosuppression (Neutropenia, Thrombocytopenia, Anemia): 95%
Febrile Neutropenia/Infection: 60%
Mucositis/Stomatitis: 60%
Nausea/Vomiting: 80%
Fatigue: 85%
Alopecia: 90%
Neurotoxicity (Vincristine-induced): 40%
Cardiotoxicity (Doxorubicin-induced): 10%

Annual Cost of Care

Drug Cost

$150,000

Monitoring

$80,000

Side Effects

$70,000

Total Annual

$300,000

Cost-Effectiveness

GOOD

QALYs Gained

5

ICER

$60,000/QALY

Cost per Remission

$352,941.18

Cost per Responder

$333,333.33

Treatment Outcomes
Efficacy Outcomes
Overall Effectiveness
+87%
Response Rate
+90%
Remission Rate
+85%
Common Side Effects
Myelosuppression (Neutropenia, Thrombocytopenia, Anemia)
+95%
Febrile Neutropenia/Infection
+60%
Mucositis/Stomatitis
+60%

Clinical Trial Phases:

Phase 2Phase 3Phase 4
4
Dose-adjusted EPOCH with Rituximab (DA-EPOCH-R)
85% Effectiveness• 90% Confidence• 25% Safety• 3 trials• 3K participants
HIGH EvidenceGood ValueDose: Dose-adjusted based on nadir counts, intravenously
Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe

Time to Effect

Within weeks of starting cycles

Duration

5-6 months (6-8 cycles)

Response Rate

85%

Remission Rate

75%

Common Side Effects:

Myelosuppression (Neutropenia, Thrombocytopenia, Anemia): 90%
Febrile Neutropenia/Infection: 50%
Mucositis/Stomatitis: 55%
Nausea/Vomiting: 75%
Fatigue: 80%
Alopecia: 90%
Neurotoxicity (Vincristine-induced): 30%
Cardiotoxicity (Doxorubicin-induced): 7%

Annual Cost of Care

Drug Cost

$120,000

Monitoring

$70,000

Side Effects

$70,000

Total Annual

$260,000

Cost-Effectiveness

GOOD

QALYs Gained

4.5

ICER

$57,777/QALY

Cost per Remission

$346,666.67

Cost per Responder

$305,882.35

Treatment Outcomes
Primary Outcomes
Largest Tumor Lesion Diameter8 cm
-90% (-7.2 cm)
Lactate Dehydrogenase (LDH)800 U/L
-85% (-680 U/L)
Bone Marrow Blast Percentage40% involvement
-100% (-40% involvement (clearance))
Secondary Benefits
ECOG Performance Status2
-100% (-2 points (to 0))
FACT-L (Functional Assessment of Cancer Therapy - Lymphoma) Score90/156
+20% (+18 points)
Body Weight60 kg (following unintentional weight loss)
+10% (+6 kg)
Common Side Effects
Myelosuppression (Neutropenia, Thrombocytopenia, Anemia)
+90%
Febrile Neutropenia/Infection
+50%
Mucositis/Stomatitis
+55%

Clinical Trial Phases:

Phase 2Phase 3Phase 4
5
Autologous Stem Cell Transplant (ASCT)
50% Effectiveness• 90% Confidence• 25% Safety• 5 trials• 2K participants
MODERATE EvidenceModerate ValueDose: High-dose conditioning chemotherapy followed by stem cell reinfusion
Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe

Time to Effect

Weeks to months for engraftment and recovery

Duration

3-4 weeks inpatient for transplant, months for recovery

Response Rate

%

Remission Rate

40%

Common Side Effects:

Profound Myelosuppression: 95%
Severe Febrile Neutropenia/Infection: 80%
Severe Mucositis/Stomatitis: 85%
Nausea/Vomiting: 90%
Fatigue: 90%
Organ Toxicity (Renal, Hepatic, Pulmonary): 30%
Secondary Malignancies (long term): 7%

Annual Cost of Care

Drug Cost

$75,000

Monitoring

$200,000

Side Effects

$125,000

Total Annual

$400,000

Cost-Effectiveness

MODERATE

QALYs Gained

4

ICER

$100,000/QALY

Cost per Remission

$1,000,000

Treatment Outcomes
Primary Outcomes
2-Year Progression-Free Survival (PFS) RateExpected 2-year PFS for relapsed/refractory Burkitt lymphoma with conventional salvage (e.g., 20%)
+125% (+25 percentage points (from 20% to 45%))
2-Year Overall Survival (OS) RateExpected 2-year OS for relapsed/refractory Burkitt lymphoma with conventional salvage (e.g., 25%)
+120% (+30 percentage points (from 25% to 55%))
2-Year Relapse/Progression RateExpected 2-year relapse rate for relapsed/refractory Burkitt lymphoma with conventional salvage (e.g., 75%)
-46.67% (-35 percentage points (from 75% to 40%))
Complete Metabolic Response (CMR) Rate on PET/CT Post-ASCTCMR rate after conventional salvage for relapsed/refractory Burkitt lymphoma (e.g., 30%)
+100% (+30 percentage points (from 30% to 60%))
Secondary Benefits
EORTC QLQ-C30 Global Health Status Score (6 months post-ASCT)Pre-ASCT score (e.g., 55/100, higher is better QoL)
+27.27% (+15 points (from 55 to 70))
Karnofsky Performance Status (KPS) Score (6 months post-ASCT)Pre-ASCT score (e.g., 70/100, higher is better function)
+28.57% (+20 points (from 70 to 90))
Rate of Return to Work or Normal Activities (12 months post-ASCT)Rate before ASCT due to illness/treatment (e.g., 20%)
+200% (+40 percentage points (from 20% to 60%))
Common Side Effects
Profound Myelosuppression
+95%
Severe Febrile Neutropenia/Infection
+80%
Severe Mucositis/Stomatitis
+85%

Clinical Trial Phases:

Phase 2Phase 3Phase 4